Navigation Links
Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Date:1/31/2008

CALGARY, Jan. 31 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has met the initial criteria to proceed to full enrolment in its U.S. Phase II trial to evaluate the intravenous administration of REOLYSIN(R) in patients with various sarcomas that have metastasized to the lung.

According to the trial protocol, to proceed to full enrolment of 52 patients, Oncolytics had to demonstrate that at least one patient in the first 38 patients treated experienced a complete or partial response, or stable disease for greater than six months. The third patient treated in the study was demonstrated to have stable disease by RECIST criteria for more than six months as measured by CT scan. A PET scan taken at the same time showed that any residual mass was metabolically inert.

A total of 12 patients have received REOLYSIN(R) treatment to date, with five remaining on study. All 12 patients have been treated at the Cancer Therapy and Research Center, University of Texas Health Science Center in San Antonio, Texas (CTRC at UTHSCSA).

"We are very pleased to proceed to the second stage of the REOLYSIN(R) study," said Dr. Monica Mita, Principal Investigator at CTRC at UTHSCSA. "This unique targeted compound has met our expectations so far in terms of both tolerability and efficacy endpoints and we feel it is very important to continue to offer this agent to our patients."

"While still early, these are very encouraging results," said Dr. Karl Mettinger, Chief Medical Officer of Oncolytics. "There are few treatment options for patients with bone or soft tissue cancers, and we are pleased that the trial participants appear to be benefiting from REOLYSIN(R) treatment."

Patients are expected to be enrolled at three additional sites, which include the Montefiore Medical Center/Albert Einstein College of Medicine in the Bronx, New York, the University of Michigan Comprehensive Cancer Center
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
3. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
6. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
7. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
10. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
11. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... The human skin is the largest organ, yet many ... part. Similar to the liver, or heart, the skin must ... grow. Recent reports from the mankatofreepress.com explained how caring for ... as other life supporting organs. The article suggests several types ... increase the appearance of skin, and fight off acne causing ...
(Date:6/18/2013)... The Pistoia Alliance is ... biomolecular representation standard software toolkit and editor under ... HELM (Hierarchical Editing Language for Macromolecules) enables the ... proteins, nucleotides, antibody drug conjugates) whose size and ... impractical or unusable. HELM solves this problem through ...
(Date:6/18/2013)... 2013 The "Bioinformatics Market By Sector (Molecular ... Tools & Data Analysis Services) & Application (Genomics, Proteomics & ... Market Drivers, Restraints, and Opportunities in North America ... and Rest of World. Browse ... 22 Figures 364 Pages and ...
(Date:6/18/2013)... DUBLIN , June 18, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/5g3rx5/dna_sequencing ) has announced the addition of ... Markets and Companies " to their offering. ... This report briefly reviews basics of human ... their applications. Current large and small sequencers ...
Breaking Biology Technology:Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin 2The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools 2Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2
... SEATTLE, May 5 On Thursday, May 8, ... Pacific members of,Cell Therapeutics, Inc.,s (CTI) (Nasdaq: ... conference call to discuss the company,s 2008 first,quarter ... Numbers Thursday, May 8 8:30 a.m. ...
... May 5 VaxGen,Inc. (OTC Bulletin Board: VXGN.OB), ... sale of all assets and rights related to ... and,related technology to Emergent BioSolutions, Inc. Under the ... million upon execution of,the definitive agreement and may ...
... shrink, even tiny defects in the lines, dots and ... performance. Princeton engineers have now found a way to ... could dramatically improve chip quality without increasing fabrication cost. ... of Nature Nanotechnology, enables more precise shaping of microchip ...
Cached Biology Technology:VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc. 2Melting defects could lead to smaller, more powerful microchips 2Melting defects could lead to smaller, more powerful microchips 3Melting defects could lead to smaller, more powerful microchips 4
(Date:6/19/2013)... expected to contribute to a very large and potentially ... a University of Michigan ecologist and colleagues who released ... Chesapeake Bay. , The Gulf forecast, one of two ... for an oxygen-depleted, or hypoxic, region of between 7,286 ... the 10 largest on record. , The low end ...
(Date:6/18/2013)... Faculty of Medicine have discovered a mechanism that is ... a component of blood typically associated with clotting, were ... detection, seal it off from the rest of the ... Immunology this week, provide the science community with ... has known that platelets do participate in immunity, but ...
(Date:6/18/2013)... very large "dead zone" in the Gulf of Mexico ... Chesapeake Bay this year, based on several NOAA-supported forecast ... Louisiana State University, and the Louisiana Universities Marine ... hypoxic "dead" zone will be between 7,286 and 8,561 ... largest recorded. That would range from an area the ...
Breaking Biology News(10 mins):U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 2U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 3U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 4Immunity mechanism discovered 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4
... tissue in those spare tires and lower belly pooches ... is an active organ that sends chemical signals to ... heart attacks, cancer, and other diseases. They are reporting discovery ... to be secreted into the blood by human fat cells ...
... LONDON, Oct. 13 The 2010 Frost & ... Verification Components and Systems is presented to Fingerprint ... ) (Logo:  http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO) "For ... in the biometrics industry with the prime focus ...
... October 13, 2010) Before Alzheimer,s patients experience memory loss, ... A new study in mouse models by researchers ... mitochondria -- the powerhouses of the cell -- are one ... appeared in the online Early Edition of PNAS, also found ...
Cached Biology News:Frost & Sullivan Honours Fingerprint Cards AB with Product Line Strategy Award 2Frost & Sullivan Honours Fingerprint Cards AB with Product Line Strategy Award 3Frost & Sullivan Honours Fingerprint Cards AB with Product Line Strategy Award 4Early role of mitochondria in AD may help explain limitations to current beta amyloid hypothesis 2
Rabbit anti-Junctophilin-4 (C-term)...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
... Crystal / Mount is the standard ... is designed especially for the permanent preservation ... sections. It is easy to use and ... is the first aqueous mounting medium that ...
... development to targets including proteins and to ... cancer-specific surface antigens. A&Gs service is ... in approximately 40 days (duration may vary ... Phase I: Immunization, test bleed and ...
Biology Products: